Efficacy of cefquinome and a combination of cloxacillin and ampicillin for treatment of dairy cows with Streptococcus agalactiae subclinical mastitis

Autor(es)

Rossi, Rodolfo Santos ^[1] ; Amarante, Ariadne Ferreira ^[1] ; Guerra, Simony Trevisan ^[1] ; Latosinski, Giulia Soares ^[1] ; Rossi, Bruna Fernanda ^[2] ; Mores Rall, Vera Lucia ^[2] ; de Figueiredo Pantoja, Jose Carlos ^[1]

Afiliação do(s) autor(es)

^[1] Sao Paulo State Univ UNESP, Dept Vet Hyg & Publ Hlth, Sch Vet Med & Anim Sci, Botucatu, SP - Brazil

^[2] Sao Paulo State Univ UNESP, Dept Microbiol & Immunol, Inst Biosci, Botucatu, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: PLoS One; v. 14, n. 4 APR 25 2019.
• Citações Web of Science: 0

Resumo

A randomized clinical trial was conducted to assess efficacy of intramammary cloxacillin and ampicillin (CLOXIMM), intramammary cefquinome (CEFIMM), and intramuscular cefquinome (CEFIM) to treat Streptococcus agalactiae intramammary infections (Trial 1). Subsequently, two treatment groups were extended to assess whether CLOXIMM was not inferior to CEFIMM (Trial 2). Nine farms were included in the study. Milk samples were collected from all quarters of all lactating cows for microbiological identification of S. agalactiae. Positive cows were randomly allocated into four groups: CLOXIMM, CEFIMM, CEFIM, or negative control (CONTROL). Study outcomes were bacteriological cure at 14 (CURE14), 21 (CURE21), and 14 and 21 (CURE1421) days after treatment onset, and somatic cell count. Logistic regression was used to estimate the odds of cure between each treatment and CONTROL. Non-inferiority analysis was performed considering a one-sided 95% confidence interval (CI) and non-inferiority margins (Delta) of 0.10, 0.15, 0.20, and 0.25. Adjusted S. agalactiae bacteriological cure for CLOXIMM, CEFIMM, CEFIM, and CONTROL was 86, 98, 55, and 25% at day 14; 82, 93, 52, and 0% at day 21; and 82, 92, 40, and 0% at days 14 and 21, respectively. Treatment with CLOXIMM and CEFIMM resulted in greater bacteriological cure rates, as compared with CEFIM or CONTROL, which does not justify the use of CEFIM in S. agalactiae eradication programs. The CURE14 difference between CEFIMM and CLOXIMM was of 12.1 percentage points (95% CI: 0.056-0.184). CLOXIMM was considered not inferior to CEFIMM for Delta = 0.20 or 0.25 and inconclusive for Delta = 0.10 or 0.15. Thus, it should be pondered by veterinarians whether an expected 12.1 (5.6-18.4) percentage points increase in cure rate would justify the use of a fourth-generation cephalosporin, as opposed to a combination of traditional IMM drugs (cloxacillin and ampicillin) to treat S. agalactiae subclinical mastitis. (AU)

• Processo FAPESP: 15/21157-0 - Novas estratégias para o aumento da eficácia de programas de erradicação de Streptococcus agalactiae em rebanhos leiteiros
• Beneficiário: José Carlos de Figueiredo Pantoja
• Modalidade de apoio: Auxílio à Pesquisa - Regular